深静脉血栓的新兴分子标:从炎症到凝血
Zhuying Zhang1, Jiaqi Hu2, Yanfeng Bai1
1Department of Orthopedics, Jiaxing Second Hospital, Jiaxing, People's Republic of China.
Hematology (Amsterdam, Netherlands)
|September 3, 2025
概括
炎症会导致深静脉血栓形成,从而导致免疫血栓形成. 针对像中性粒细胞外陷 (NETs) 和P-选择素这样的分子,可能会提供除了抗凝剂之外的新疗法.
科学领域:
- 血管生物学
- 免疫学
- 血液学
背景情况:
- 深静脉血栓 (DVT) 是一种主要的血管疾病,具有严重的并发症,如肺栓塞.
- 炎症越来越多地被认为是DVT发病的关键驱动因素,与通过免疫血栓形成的凝血有关.
研究的目的:
- 审查新出现的分子点,这些点在DVT中的炎症和凝血途径.
- 探索针对这些分子的新型治疗方法的治疗潜力.
主要方法:
- 综合了最近关于DVT分子点的研究成果.
- 专注于中性粒细胞外陷 (NETs),PAD4,P选择蛋白,HMGB1,组织因子 (TF),补充C3和NLRP3炎症体.
主要成果:
- 通过提供支架,激活XII因子和稳定血栓,NETs促进血栓形成.
- PAD4,P-选择蛋白,HMGB1,TF,补充C3和NLRP3炎症体是DVT炎症-凝血交叉的关键媒介.
- 临床前数据显示有前途, 但治疗转化面临诸如物种差异和非目标效应等挑战.
结论:
- 针对已识别的分子, 有可能开发出避免出血的DVT疗法.
- 欧米克和查技术的创新可能会加快对DVT的新治疗目标的发现.
相关概念视频
Venous Thrombosis I: Introduction
40
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
40
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
34
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
34
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K


